1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. ๐ Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. ๐ Posts
Discussion
1. Investment Snapshot
2. Capital Structure
3. What does Latigo Biotherapeutics, Inc. do?
4. Valuation
5. ๐ Posts
Discussion
Symbol
LTGO
Event Date
2026-08-07
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
$18.00
Shares Offered
19.2M
Shares Outstanding Pre-IPO
44.15M
60.15M
$1.1B
31.9%
Implied Upside vs Midpoint
Description
We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and most pervasive therapeutic markets in the United States, driving an estimated 250 million prescriptions annually across acute and chronic settings; however, a continued reliance on opioids has contributed to a persistent public health crisis with significant societal and economic costs. Our two most advanced candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. We are also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. Beyond Nav1.8, we plan to explore other ion channel targets involved in pain transmission that offer complementary mechanisms of action, enabling potential use in multi-modal treatment to enhance pain relief or address diverse pain etiologies. Pain is heterogeneous and can be experienced in a chronic or acute manner, within both musculoskeletal and neuropathic pain. Our initial development efforts are focused on musculoskeletal pain, where we believe there is significant unmet need and an opportunity for differentiated clinical benefit utilizing a Nav1.8 mechanism. We aim to build one of the broadest pipelines of pain therapeutics, which we believe, combined with our management teamโs deep expertise in pain biology, clinical translation and trial execution, positions us to deliver meaningful patient benefit and to change the current treatment paradigm of pain medicines. Our lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-001 is currently in development as a potential treatment for moderate to severe acute pain, including postoperative pain, and is intended for use as needed for up to 30 days. We believe LTG-001 will address a critical unmet need in a high-volume market where opioids remain the standard of care due to a lack of effective, non-addictive alternatives with rapid onset. The 2025 U.S. Food and Drug Administration (FDA) approval of the first Nav1.8 inhibitor, suzetrigine (Journavx), provides a clear development and regulatory precedent for this therapeutic class. The FDA typically has required demonstration of efficacy in at least one soft tissue model and one hard tissue (bony) model to support an approved label indication for treatment of moderate to severe acute pain, including postoperative pain. The most common models used to demonstrate efficacy in pivotal trials have been abdominoplasty (soft tissue) and bunionectomy (hard tissue), and this has informed our development strategy. We recently received positive data for LTG-001 in our randomized, placebo and comparator-controlled trial in 343 patients undergoing abdominoplasty. This clinical trial met its primary endpoint and key secondary endpoints with high statistical significance. Based on our discussions with the FDA, the abdominoplasty trial may serve as one of the two pivotal adequate well-controlled trials required to demonstrate efficacy to support approval of LTG-001 for the treatment of moderate to severe acute pain, including postoperative pain. Key highlights from the abdominoplasty trial include: โข Met primary endpoint and achieved ~50% greater analgesic effect than Vicodin, the opioid comparator: High dose LTG-001 (450mg loading followed by 300mg every 12 hours) met its primary endpoint of Summed Pain Intensity Difference from 0 to 48 hours (SPID48) versus placebo, achieving a 62.1-point (p<0.001) improvement versus placebo and numerically exceeding the SPID48 of the trialโs opioid comparator, hydrocodone bitartrate/acetaminophen (HB/APAP), which is commonly known as Vicodin, which was a 40.9-point improvement versus placebo (p=0.001). โข Achieved rapid onset of meaningful pain relief: Median time to a ≥2-point reduction in Numeric Pain Rating Scale (NPRS) score was 52 minutes with high dose LTG-001, and 83 minutes for HB/APAP, the opioid comparator in the trial. โข Demonstrated opioid sparing: 52.3% of patients receiving high dose LTG-001 remained opioid-free during the 48-hour treatment period (p<0.001). Pain experienced by these patients was sufficiently managed by LTG-001 alone and required no rescue medicine. In the placebo group, only 22.1% remained opioid-free. โข Dose response observed: Low dose LTG-001 (300mg loading followed by 150mg every 12 hours) also demonstrated statistically significant improvement versus placebo (SPID48 of 37.8; p=0.003), roughly comparable to the effect of HB/APAP, the opioid comparator in the trial. LTG-001 has been generally well-tolerated and has generated favorable clinical pharmacology data characterized by limited drugโdrug interaction (DDI) potential and balanced renal and hepatic clearance in preclinical studies. In order to submit a New Drug Application (NDA) seeking FDA approval of LTG-001 as a potential treatment for moderate to severe acute pain, including postoperative pain, we are also required to conduct an open-label safety trial to attain a certain number of safety exposures at the intended commercial dose and to demonstrate safety across a mix of demographics and surgical settings to more adequately match the real-world setting. We plan to initiate a placebo-controlled Phase 3 trial in participants undergoing bunionectomy and an open-label Phase 3 safety trial exploring LTG-001 within a broader population of patients with moderate to severe acute pain across a variety of post-surgical and non-surgical settings in the second half of 2026, with topline results expected in the second half of 2027. In addition to oral dosing, LTG-001 is also being advanced as a potential intravenous (IV) formulation to support use in hospital settings and enable transition from inpatient postoperative care to outpatient pain management. LTG-321 is our next-generation candidate for the inhibition of Nav1.8, initially being developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). LTG-321 is structurally distinct from LTG-001. LTG-321โs differentiated profile may enable a lower effective dose and once-daily dosing, characteristics we believe are particularly important for a chronic-use setting. In the Phase 1 trial, data as of May 15, 2026 showed that LTG-321 demonstrated robust pharmacodynamic activity as measured by an increased pain tolerance threshold, with continued activity at 24 hours after a single dose in the cold pressor test (CPT). We have refined the CPT methodology and it has provided a quantifiable and repeatable clinical endpoint that has translated into clinical trial outcomes for our lead product candidate. We have initiated a Phase 2 proof-of-concept trial investigating LTG-321 in patients with OA of the knee. The trial is designed as a randomized, double-blind, placebo controlled within subject crossover trial in approximately 120 patients with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain as the primary endpoint to establish clinical proof-of-concept in chronic musculoskeletal pain and inform subsequent pivotal trial design. We expect to report topline results in the second half of 2027. Our earlier stage pipeline consists of LTG-418, a next-generation Nav1.8 inhibitor being developed for the treatment of acute and chronic pain. LTG-418 is structurally distinct from LTG-001 and LTG-321 and is predicted to have a dose which will be substantially lower than the expected doses for LTG-001 and LTG-321. We believe the predicted lower dose with LTG-418 is one of the features that may enable additional opportunities for other formulations and routes of administration including gels, patches, eye drops, inhalers and injectables, expanding our reach within the pain market and offering patients therapeutic options beyond oral and IV delivery. Suitable tolerability was demonstrated in a completed 14-day non-GLP toxicology study and in the in-life portion of an ongoing 14-day non-GLP toxicology study in non-human primates (NHPs). We are also in discovery of additional ion channel modulators involved in peripheral transmission of pain that represent potential complementary mechanisms of action to Nav1.8 inhibition for additional pain relief including in other chronic pain etiologies like neuropathic pain. Our differentiated approach to addressing the shortcomings of current pain management and drug development is built on overcoming challenges in developing novel pain medicines through development of preclinical tools including electrophysiology in human DRG neurons and NHP microneurography to measure the effect of compounds on pain target engagement, optimization of CPT as a reliable biomarker that allows rapid in-human evaluation of analgesic effect with minimal investment and deep expertise in clinical trial design and execution. Musculoskeletal pain is one of the most prevalent healthcare challenges in the United States and can be of an acute nature or, when persistent, become chronic. Acute pain from surgery, injury and trauma drove approximately 80 million adults in the United States to receive acute musculoskeletal pain prescriptions in 2022, while common forms of chronic pain conditions like OA and Chronic Lower Back Pain affected more than 60 million Americans in 2023. Neuropathic pain arises from disease or dysfunction in the nervous system and is predominantly chronic in nature, differing fundamentally in pathophysiology and likely therapeutic approach. In the United States, it is estimated that approximately 10 million patients were prescribed a medicine for peripheral neuropathic pain in 2022. Current treatment options for pain management such as NSAIDs and opioids require difficult tradeoffs between efficacy, safety, tolerability and risk of addiction, leaving many patients either undertreated or exposed to therapies with significant limitations or addiction potential. Further, the widespread reliance on opioids for pain management has resulted in an opioid epidemic that is not only a medical crisis but also a profound societal and economic burden. Opioids carry a significant risk of addiction and overdose, even with short-term use. In response, legislation has been enacted to limit prescription duration and strengthen controls due to concerns around misuse and dispersion. Beyond addiction, opioids are also associated with significant safety and tolerability issues, including sedation and a high incidence of gastrointestinal adverse effects such as nausea and vomiting. Role of Nav1.8 and Unmet Need in Current Nav1.8 Inhibitors Nav1.8 is a voltage-gated sodium channel that plays a significant role in transmission of pain, and the role of Nav1.8 as a pain target has been genetically and clinically validated. Since Nav1.8 is substantially expressed in peripheral nerve tissue and not in the brain or other tissue, its inhibition has not been associated with addiction or severe tolerability concerns. The approval of Journavx (suzetrigine) in January 2025 represented a breakthrough in pain management as a first-in-class non-opioid, non-addictive selective pain signal inhibitor for Nav1.8. Suzetrigine represents a safer non-opioid alternative, but is limited by efficacy, slow onset and contraindications. We believe that these limitations may limit uptake. --- We were originally incorporated under the laws of the State of Delaware in November 2018. Our principal executive offices are located at 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, California 91320, and our telephone number is (805) 716-2927. Our website is www.latigobio.com.
Post-IPO economic shares by class, valued at the offer midpoint.
| Class | Shares | % Economic | Est. value |
|---|---|---|---|
Class A Common Stock (listed) 1 vote per share ยท None | 60.15M | 100.0% | $1.1B |
| Total economic shares | 60.15M | 100% | $1.1B |
Redeemable Convertible Preferred Stock Pre-conversion โ already in the listed class | 41.16M |
Latigo Biotherapeutics disclosed up to $331.2M in shares in a recent SEC filing, prompting questions about its valuation, lead investors, and IPO plan, resulting in a neutral market sentiment.
AI per-post analysis: 0 positive, 0 negative, 1 neutral (engagement-weighted aggregate).